TY - JOUR
T1 - Bovine serum albumin nanoparticles induce histopathological changes and inflammatory cell recruitment in the skin of treated mice
AU - da Silva, Natalia Ingrid Oliveira
AU - Salvador, Ezequiel Aparecido
AU - Rodrigues Franco, Isabella
AU - de Souza, Gabriel Augusto Pires
AU - de Souza Morais, Stella Maria
AU - Prado Rocha, Raissa
AU - Dias Novaes, Rômulo
AU - Paiva Corsetti, Patrícia
AU - Malaquias, Luiz Cosme Cotta
AU - Leomil Coelho, Luiz Felipe
N1 - Publisher Copyright:
© 2018 Elsevier Masson SAS
PY - 2018/11
Y1 - 2018/11
N2 - Albumin is a natural, biocompatible, biodegradable and nontoxic polymer and due to these features, nanoparticles made of albumin are a good system for drug or antigen delivery. Polymeric nanoparticles are being widely explored as new vaccines platforms due to the capacity of those nanoparticles to prime the immune system by providing sustained release of the antigen after injection. Biodegradable nanoparticles associated with proteins represent a promising method for in vivo delivery of vaccines. In our previous studies, bovine serum albumin nanoparticles (BSA-NPs) were identified as a promising system for in vivo delivery of microbial antigens. The aim of this work was to show the effect of BSA-NPs on skin after nanoparticles administration. The pro-inflammatory activity of BSA-NPs was evaluated using in vivo models. BSA-NPs are easily uptake by macrophagic RAW 264.7 and BHK-21 cells without any significant cytotoxicity. Histological examination of skin sections from BSA-NPs-treated mice revealed intense cellular infiltration, increased skin thickness, follicular hypertrophy, vascular congestion and marked collagenesis. Mice immunized with recombinant non-structural protein 1 (rNS1) from Dengue virus 1 and BSA-NPs showed a high seroconversion rate if compared to animals immunized only with rNS1. Therefore, the effect of BSA-NPs on skin after BSA-NPs administration has a biotechnological relevance to the rational design of vaccine formulations based on albumin nanocarriers. However in the next years future studies should be carried out to best characterize the effect of BSA-NPs on dendritic cells and establish the role of these nanoparticles as a new vaccine platform for infectious diseases or cancer.
AB - Albumin is a natural, biocompatible, biodegradable and nontoxic polymer and due to these features, nanoparticles made of albumin are a good system for drug or antigen delivery. Polymeric nanoparticles are being widely explored as new vaccines platforms due to the capacity of those nanoparticles to prime the immune system by providing sustained release of the antigen after injection. Biodegradable nanoparticles associated with proteins represent a promising method for in vivo delivery of vaccines. In our previous studies, bovine serum albumin nanoparticles (BSA-NPs) were identified as a promising system for in vivo delivery of microbial antigens. The aim of this work was to show the effect of BSA-NPs on skin after nanoparticles administration. The pro-inflammatory activity of BSA-NPs was evaluated using in vivo models. BSA-NPs are easily uptake by macrophagic RAW 264.7 and BHK-21 cells without any significant cytotoxicity. Histological examination of skin sections from BSA-NPs-treated mice revealed intense cellular infiltration, increased skin thickness, follicular hypertrophy, vascular congestion and marked collagenesis. Mice immunized with recombinant non-structural protein 1 (rNS1) from Dengue virus 1 and BSA-NPs showed a high seroconversion rate if compared to animals immunized only with rNS1. Therefore, the effect of BSA-NPs on skin after BSA-NPs administration has a biotechnological relevance to the rational design of vaccine formulations based on albumin nanocarriers. However in the next years future studies should be carried out to best characterize the effect of BSA-NPs on dendritic cells and establish the role of these nanoparticles as a new vaccine platform for infectious diseases or cancer.
KW - Albumin
KW - Immunization
KW - Nanoparticles
KW - Skin inflammation
UR - http://www.scopus.com/inward/record.url?scp=85054321863&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054321863&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2018.08.106
DO - 10.1016/j.biopha.2018.08.106
M3 - Article
C2 - 30257346
AN - SCOPUS:85054321863
SN - 0753-3322
VL - 107
SP - 1311
EP - 1317
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
ER -